Moleculin Biotech Inc
MBRX0.267USD
-0.315-54.20%
Close 06/20, 16:00（ET）Quotes delayed by 15 min
3.77MMarket Cap
LossP/E TTM
More Details of Moleculin Biotech Inc Company
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Company Info
Ticker SymbolMBRX
Company nameMoleculin Biotech Inc
IPO dateJun 02, 2016
Founded at2015
CEOMr. Walter V. Klemp
Number of employees17
Security typeOrdinary Share
Fiscal year-endJun 02
Address5300 Memorial Dr Ste 950
CityHOUSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code77007
Phone17133005160
Websitehttps://moleculin.com/
Ticker SymbolMBRX
IPO dateJun 02, 2016
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
8.00K
--
Mr. Robert E. George
Mr. Robert E. George
Independent Director
Independent Director
979.00
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Independent Director
Independent Director
--
--
Mr. Jonathan P. Foster
Mr. Jonathan P. Foster
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Elizabeth A. (Liz) Cermak
Ms. Elizabeth A. (Liz) Cermak
Independent Director
Independent Director
--
--
Dr. Joy Yan, LPN
Dr. Joy Yan, LPN
Independent Director
Independent Director
--
--
Mr. Michael D. Cannon
Mr. Michael D. Cannon
Independent Director
Independent Director
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Walter V. Klemp
Mr. Walter V. Klemp
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
8.00K
--
Mr. Robert E. George
Mr. Robert E. George
Independent Director
Independent Director
979.00
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Independent Director
Independent Director
--
--
Mr. Jonathan P. Foster
Mr. Jonathan P. Foster
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Elizabeth A. (Liz) Cermak
Ms. Elizabeth A. (Liz) Cermak
Independent Director
Independent Director
--
--
Dr. Joy Yan, LPN
Dr. Joy Yan, LPN
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jun 4
Updated: Wed, Jun 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.85%
Cetera Investment Advisers LLC
0.50%
Klemp (Walter V.)
0.41%
LPL Financial LLC
0.33%
The Vanguard Group, Inc.
0.22%
Other
89.70%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
8.85%
Cetera Investment Advisers LLC
0.50%
Klemp (Walter V.)
0.41%
LPL Financial LLC
0.33%
The Vanguard Group, Inc.
0.22%
Other
89.70%
Shareholder Types
Shareholders
Proportion
Hedge Fund
8.86%
Investment Advisor
1.02%
Individual Investor
0.56%
Investment Advisor/Hedge Fund
0.40%
Corporation
0.16%
Venture Capital
0.08%
Bank and Trust
0.07%
Research Firm
0.03%
Other
88.81%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
57
661.71K
4.73%
+46.20K
2024Q4
59
564.93K
7.40%
-45.69K
2024Q3
59
560.84K
19.72%
+96.29K
2024Q2
59
414.10K
17.96%
+17.19K
2024Q1
59
339.02K
15.22%
-103.46K
2023Q4
61
426.81K
19.16%
+202.97K
2023Q3
59
208.67K
10.51%
-20.61K
2023Q2
62
216.12K
10.93%
-59.32K
2023Q1
65
258.04K
13.11%
-14.27K
2022Q4
71
255.76K
13.40%
-6.75K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
317.59K
2.27%
+27.59K
+9.51%
Dec 31, 2024
Klemp (Walter V.)
57.03K
0.41%
--
--
Mar 28, 2025
LPL Financial LLC
41.22K
0.29%
+5.11K
+14.16%
Dec 31, 2024
The Vanguard Group, Inc.
30.93K
0.22%
-40.47K
-56.68%
Dec 31, 2024
Geode Capital Management, L.L.C.
22.02K
0.16%
+206.00
+0.94%
Dec 31, 2024
AnnaMed, Inc.
15.90K
0.11%
--
--
Mar 28, 2025
BlackRock Institutional Trust Company, N.A.
12.38K
0.09%
-95.00
-0.76%
Dec 31, 2024
Foster (Jonathan P.)
11.36K
0.08%
--
--
Mar 28, 2025
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
Date
Type
Ratio
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Mar 19, 2024
Merger
15<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
Jan 29, 2021
Merger
6<1
